Genelux (GNLX) vs Vivani Medical (VANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vivani Medical (VANI) has outperformed Genelux (GNLX) over the past year, losing 11.3% versus a loss of 54.9%. Genelux is the larger company by market cap ($115.8 million vs $112.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | VANI |
|---|---|---|
| Share price | $2.56 | $1.25 |
| Market cap | $115.83M | $112.75M |
| 1-day change | +2.40% | +1.63% |
| YTD return | -41.28% | +1.63% |
| 1-year return | -54.85% | -11.35% |
| 5-year return | — | -85.73% |
| EPS (TTM) | $-0.89 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.54 | $1.92 |
| 52-week low | $2.29 | $0.923 |
| Distance from 52-week high | -70.01% | -34.90% |
| Analyst consensus | none | none |
| Avg. price target upside | +635.55% | +206.40% |
| Average volume | 276.60K | 228.48K |
| Shares outstanding | 45.25M | 90.20M |
| Employees | 25 | 42 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VANI has outperformed GNLX by 43.5 percentage points over the past year.
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About Vivani Medical
VANI stock →Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 42 employees
GNLX vs VANI FAQ
Which is bigger, Genelux or Vivani Medical?
Genelux (GNLX) is larger, with a market capitalization of $115.83M compared with $112.75M for Vivani Medical (VANI).
Which stock has performed better over the past year, GNLX or VANI?
VANI returned -11.35% over the past 12 months, compared with -54.85% for GNLX (price return, excluding dividends). Past performance does not predict future results.
Are Genelux and Vivani Medical in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Genelux and Biotechnology: Electromedical & Electrotherapeutic Apparatus for Vivani Medical.